Health
globalreutersSeptember 29, 20241 Mins read
Sanofi and Regeneron Biologic Drug Dupixent Notches a New FDA Approval in COPD
globalreutersSeptember 29, 20241 Mins read 
Dupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in smokers. It’s the sixth FDA-approved indication for the blockbuster drug.
The post Sanofi and Regeneron Biologic Drug Dupixent Notches a New FDA Approval in COPD appeared first on MedCity News.
Related Articles
These 3 Mindset Shifts Will Help Providers Deliver Consumer-Driven Care, Investor Says
One of the most important things providers can do on the journey...
IVF Treatment in India:A complete Guide to Costs, Success Rates and Clinics
Thinking about in-vitro fertilization (IVF) but unsure about costs, success rates, and...
Top Hospitals for Pacemaker Implantation Surgery in India: What you need to know?
Pacemaker implantation is a life-saving procedure for people with irregular heart rhythms....
Links
When is a public health problem a crisis? LA has the worst...
Leave a comment